JPMorgan Boosts Target on Vivus (VVUS), More Confidence in Approval
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $13.01 +0.23%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 24 | New: 24
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 24 | New: 24
Trade VVUS Now!
Earlier, JPMorgan lifted its price target on Overweight Vivus (NASDAQ: VVUS) from $30 to $35 after rival rena Pharma (NASDAQ: ARNA) received FDA approval for Belviq was approved.
The firm has increased conviction in the approval of Qnexa by the July 17th PDUFA date following the news.
"Belviq's approval enhances our already high confidence that Qnexa's regulatory review will conclude next month with a similar positive outcome," the analyst said. "This is based on the drug's seemingly more favorable discussion by an FDA AdCom (although both had overwhelmingly positive votes), superior efficacy vs. Belviq (~7-10% vs. ~3-3.5%), and availability of the generic components."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $28.33 yesterday, with a 52 week range of $6.13-$29.42.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm has increased conviction in the approval of Qnexa by the July 17th PDUFA date following the news.
"Belviq's approval enhances our already high confidence that Qnexa's regulatory review will conclude next month with a similar positive outcome," the analyst said. "This is based on the drug's seemingly more favorable discussion by an FDA AdCom (although both had overwhelmingly positive votes), superior efficacy vs. Belviq (~7-10% vs. ~3-3.5%), and availability of the generic components."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $28.33 yesterday, with a 52 week range of $6.13-$29.42.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Microsoft (MSFT) Rally Not Over Says UBS; Raises PT to $40
- Goldman Sachs Maintains Sell on Microsoft (MSFT)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
JPMorgan
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
